RxDoctor Payments Data

William Noland, MD

Neurology · Tucson, AZNPI 1922077668

Payments from drug & device makers

$6,243in general payments, 2019–2025

Across 342 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$567
  • Novartis$261
  • EMD Serono, Inc.$252
  • Amgen$245
  • AstraZeneca$210
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$6,14398%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,243 in reported general payments places this provider in the 55th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$1,849,400
Medicare patients
511
Services billed
46,382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4692$1,030,247
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5017$569,568
BotoxOnabotulinumtoxina247$331,404
RebifInterferon Beta-1a/Albumin21$212,790
TecfideraDimethyl Fumarate11$106,180
CopaxoneGlatiramer Acetate14$81,516
FingolimodFingolimod Hcl36$64,810
Glatiramer Acetate30$62,441
Nurtec OdtRimegepant Sulfate18$35,089
UbrelvyUbrogepant24$29,254
Emgality PenGalcanezumab-Gnlm32$27,921
Aimovig AutoinjectorErenumab-Aooe11$9,841
Gabapentin328$7,248
TrintellixVortioxetine Hydrobromide12$5,914
Levetiracetam215$5,874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy$2,225$360,658271 claims
EMD Serono, Inc.Rebif$252$212,79021 claims
BiogenTecfidera$154$106,18011 claims
Teva Pharmaceuticals USA, Inc.Copaxone$36$81,51614 claims
PfizerNurtec Odt$121$35,08918 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$48$2,16617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 388 neurology providers in Arizona.

Other neurology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →